Company intelligence / Profile preview

ProtAffin

Graz, Styria, Austriaorpha.net ↗

Ownership: Private
Development stage: Preclinical

Overview

ProtAffin developed engineered chemokines as GAG antagonists with anti-inflammatory activity. Lead product PA401, based on a modified interleukin‑8, showed preclinical efficacy in models of acute and chronic inflammation and entered a Phase 1 trial for inflammatory lung disease. The company also reported preclinical data for an MCP‑1 decoy program in multiple sclerosis models. No further clinical results are available after early-stage trials.

Therapeutic areas: ImmunologyNeurologyPulmonology
Modalities: ProteinRecombinant proteinEngineered chemokine (protein-based glycosaminoglycan antagonist)
Industry: Biotech

Drug pipeline

1 asset

PA401

Discontinued

Partnerships

No major pharmaceutical or biotech partnerships publicly disclosed.

Beyond the preview

Go deeper on ProtAffin.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ProtAffin.

Explore the full profile